In particular, findings indicate that patients with MS have significantly lower serum (Gencer et al., 2019) and cerebrospinal fluid (CSF) (Kato et al., 2003) levels of orexin A compared to normal values, suggesting that the orexin system could be an interesting target for MS treatment. This evidence concerns the gene HCRT and myeloid sarcoma.